Pradžia › Atopinis dermatitas (egzema) › Pennsylvania
Atopinis dermatitas (egzema) klinikiniai tyrimai Pennsylvania
13 tyrimai dėl Atopinis dermatitas (egzema) ieško dalyvių vietose Pennsylvania.
Miestai Pennsylvania
Oficialus tyrimo tekstas (anglų kalba)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- UPMC - Department of Dermatology- Site Number : 8400024, Pittsburgh
Renkami dalyviaiStebimasis tyrimas
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-29 · NCT07290803Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Camp Hill
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07298395A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Paddington Testing Co, Inc, Philadelphia
- UPMC Department of Dermatology, Pittsburgh
Renkami dalyviai2 fazė
Amžius nuo 18 iki 64 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07216027A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Pittsburgh
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT07003425A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Best Skin Research LLC, Camp Hill
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT07223697A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Best Skin Research, LLC, Camp Hill
- UPMC Department of Dermatology, Pittsburgh
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-08-28 · NCT07599813FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Paddington Testing Company, Philadelphia
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-07-22 · NCT06564389A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Research of Philadelphia /ID# 264972, Philadelphia
- University of Pittsburgh Medical Center /ID# 264526, Pittsburgh
- Dermatology Associates of Plymouth Meeting /ID# 267286, Plymouth Meeting
Renkami dalyviai3 fazė
Amžius nuo 18 iki 63 · Visoms lytims · Atnaujinta 2026-07-06 · NCT06389136The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
- University of Pittsburgh Medical Center, Pittsburgh
- UPMC Department of Dermatology, Pittsburgh
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-04 · NCT06928246A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Paddington Testing Co, Inc, Philadelphia
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-04 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8559, Philadelphia
- Galderma Investigational Site 7103, Philadelphia
Renkami dalyviaiStebimasis tyrimas
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT06988605Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- University of Pittsburgh Medical Center, Pittsburgh
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-12-30 · NCT00177268A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- DermDox Centers for Dermatology, Camp Hill
- University of Pennsylvania, Philadelphia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-19 · NCT06055361Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.